Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations
D Proudman, U Desai, DA Gomes… - Journal of Medical …, 2024 - Taylor & Francis
Aims Economic studies have found that public support of basic medical research provides
important long-term benefits. In response to suggestions that private pharmaceutical …
important long-term benefits. In response to suggestions that private pharmaceutical …
Is the price right? Paying for value today to get more value tomorrow
SV Ramagopalan, J Diaz, G Mitchell, LP Garrison Jr… - BMC medicine, 2024 - Springer
Background Contemporary debates about drug pricing feature several widely held
misconceptions, including the relationship between incentives and innovation, the …
misconceptions, including the relationship between incentives and innovation, the …
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
This study argues that value assessment conducted from a societal perspective should rely
on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein …
on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein …
Val (EU) xit: do we need an international ISPOR value flower?
SV Ramagopalan, M Gomes… - Journal of …, 2024 - becarispublishing.com
Background In 2016, an International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Special Task Force (STF) was formed to evaluate a number of …
Research (ISPOR) Special Task Force (STF) was formed to evaluate a number of …
Can Generalized Cost-effectiveness Analysis Leverage Meaningful Use of Novel Value Elements in Pharmacoeconomics to Inform Medicare Drug Price Negotiation?
WV Padula, P Kolchinsky - Value in Health, 2024 - Elsevier
Objectives Decision makers considering using cost-effectiveness analysis (CEA) to inform
health-technology assessment must contend with documented and controversial shortfalls of …
health-technology assessment must contend with documented and controversial shortfalls of …
Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?
J Hitch, T Denee, S Brassel, J Lee, M Michaelides… - Value in Health, 2024 - Elsevier
Objectives X-linked retinitis pigmentosa (XLRP) is a rare inherited retinal disease with no
available treatment. Gene therapies in clinical trials will pose challenges for health …
available treatment. Gene therapies in clinical trials will pose challenges for health …
Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next?
LP Garrison - Value in Health, 2024 - valueinhealthjournal.com
The 2018 report of the ISPOR Special Task Force (STF) on Value Assessment Frameworks
recommended that health technology assessment (HTA) in the United States should use …
recommended that health technology assessment (HTA) in the United States should use …
[PDF][PDF] IVI Valuing Innovation Project Expert Roundtable
P Packet - thevalueinitiative.org
Background: Over the past decades, innovation in health technologies (both pharmaceutical
and nonpharmaceutical) has been a major contributor to improved life expectancy and …
and nonpharmaceutical) has been a major contributor to improved life expectancy and …